Drug Profile
Del-1 gene therapy - Valentis
Alternative Names: DELTAVASC; VLTS 589Latest Information Update: 21 May 2007
Price :
$50
*
At a glance
- Originator Valentis
- Class Gene therapies
- Mechanism of Action Angiogenesis inducing agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ischaemic heart disorders; Peripheral arterial disorders
Most Recent Events
- 21 May 2007 Discontinued - Phase-II for Peripheral arterial disorders in USA (IM)
- 21 May 2007 Discontinued - Preclinical for Ischaemic heart disorders in USA (unspecified route)
- 21 Dec 2005 Data presented at the 78th Scientific Sessions of the American Heart Association (AHA-2005) have been added to the Vascular disorders therapeutic trials section